CIK 0001285819
- Non-accelerated filer
- Smaller reporting company
OMEROS CORP
Sign in to watch- Ticker
- OMER
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- Operating
- EIN
- 911663741
- Phone
- +1 206-676-5000
- Business address
- 201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,837,566
- in 4 filings, $626K under 10b5-1 plans
Net −$1,837,566. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 78 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-03 | JACOBSEN MICHAEL A VP Finance and CAO | Sale | −1,020 | $22.45 | $23K | 7,500 |
| 2018-01-03 | JACOBSEN MICHAEL A VP Finance and CAO | Exercise or conversion · Stock Option (Right to Buy) | −1,020 | 58,980 | ||
| 2017-12-28 | Demopulos Gregory A MD Chairman, CEO & President | Exercise or conversion | +102,040 | $2.45 | $250K | 1,987,025 |
| 2017-12-28 | Demopulos Gregory A MD Chairman, CEO & President | Exercise or conversion | +39,961 | $4.10 | $164K | 2,026,986 |
| 2017-12-28 | Demopulos Gregory A MD Chairman, CEO & President | Exercise or conversion · Stock Option (Right to Buy) | −102,040 | 0 | ||
| 2017-12-28 | Demopulos Gregory A MD Chairman, CEO & President | Exercise or conversion · Stock Option (Right to Buy) | −39,961 | 220,039 | ||
| 2017-08-21 | Kelbon Marcia S. VP Patent and General Counsel | Exercise or conversion | +8,000 | $6.05 | $48K | 176,641 |
| 2017-08-21 | Kelbon Marcia S. VP Patent and General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −8,000 | 3,000 | ||
| 2017-06-16 | JACOBSEN MICHAEL A VP Finance and CAO | Exercise or conversion | +14,000 | $9.37 | $131K | 19,500 |
| 2017-06-16 | JACOBSEN MICHAEL A VP Finance and CAO | Sale | −12,000 | $24.95 | $299K | 7,500 |
| 2017-06-16 | JACOBSEN MICHAEL A VP Finance and CAO | Exercise or conversion · Stock Option (Right to Buy) | −14,000 | 60,000 | ||
| 2017-06-16 | Hood Leroy E. MD PhD Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-06-16 | Demopulos Peter A MD Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-06-16 | Cable Thomas J. Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-06-16 | Shah Rajiv Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-06-16 | Aspiri Ray Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-06-16 | HANISH ARNOLD C Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-06-15 | JACOBSEN MICHAEL A VP Finance and CAO | Exercise or conversion | +14,000 | $9.37 | $131K | 17,500 |
| 2017-06-15 | JACOBSEN MICHAEL A VP Finance and CAO | Sale | −12,000 | $22.45 | $269K | 5,500 |
| 2017-06-15 | JACOBSEN MICHAEL A VP Finance and CAO | Exercise or conversion · Stock Option (Right to Buy) | −14,000 | 74,000 |
Page 14 of 20 · 391 trades